Mandate

Vinge advises Axcel and Accru Partners in connection with the acquisitions of Ekonomernas Hus, Revisorernas Hus, RevisionsPartner, and Censio

Vinge has advised Axcel VII and Accru Partners in connection with the parallel acquisitions of Ekonomernas hus i Sverige AB, Ekonomernas Hus Örebro AB, Revisorernas Hus Sverige AB, RevisionsPartner Skaraborg AB and Censio Tax AB.

All firms are entrepreneur-led, local businesses with expertise in accounting, tax, audit and advisory services. After the acquisitions, Accru Partners consists of 26 independent firms within the aforementioned business areas.

Vinge’s team consisted of Christina Kokko, Desirée Hagenfeldt, Egil Svensson, Michella Lina Said, Madelene Andersson and Alexander Rüdén (M&A), Simon Söderholm and Narin Melazade (Employment), Kamyar Najmi and Sofia Haggren (Banking and Finance), Mario Saad (Commercial Agreements), Elis Allmark (IT), Rebecka Målquist (Intellectual Property), Nicklas Thorgerzon (GDPR), Agnes Pigg and Hanna Kövamees (Real Property), Jonna Bondemark and David Gavatin (Regulatory), Mia Falk and Gulestan Ali (Compliance) and Jessica Öijer (Transaction Support Coordinator).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025